Molecule Details
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N
Compound NameValdecoxib
Canonical SMILESCc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
Clinical Status Clinical Multi-Target
Targets (Human+Pathogen)15
Pfam Stratification Cross-Family
Avg pChEMBL6.88
SourceBindingDB;ChEMBL;TTD_MultiTarget
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB00580
Drug NameValdecoxib
CAS Number181695-72-7
Groups approved withdrawn
ATC Codes M01AH03 G01AE10
DescriptionValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

Categories: Agents causing hyperkalemia Agents that produce hypertension Amides Analgesics Analgesics, Non-Narcotic Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Antiinflammatory and Antirheumatic Products Antiinflammatory and Antirheumatic Products, Non-Steroids Antirheumatic Agents Benzene Derivatives COX-2 Inhibitors Cyclooxygenase Inhibitors Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (weak) Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Enzyme Inhibitors Genito Urinary System and Sex Hormones Gynecological Antiinfectives and Antiseptics Musculo-Skeletal System Nephrotoxic agents Peripheral Nervous System Agents Selective Cyclooxygenase 2 Inhibitors (NSAIDs) Sensory System Agents Sulfonamides Sulfones Sulfur Compounds UGT1A9 Substrates
Cross-references: BindingDB: 13063 ChEBI: 63634 CHEMBL865 ChemSpider: 106796 PDB: COX PharmGKB: PA10226 PubChem:119607 PubChem:46506229 RxCUI: 278567 Therapeutic Targets Database: DAP001541 Wikipedia: Valdecoxib ZINC: ZINC000000006694
Target Activities (15)
Target Gene Organism Category Pfam pChEMBL Type Source
O43570 CA12 Homo sapiens Human PF00194 7.9 Ki ChEMBL;BindingDB
P35354 PTGS2 Homo sapiens Human PF03098 7.8 IC50 ChEMBL;BindingDB
Q16790 CA9 Homo sapiens Human PF00194 7.6 Ki ChEMBL;BindingDB
P00918 CA2 Homo sapiens Human PF00194 7.4 Ki ChEMBL;BindingDB
P18505 GABRB1 Homo sapiens Human PF02931 PF02932 7.4 pIC50 TTD_MultiTarget
Q9Y2D0 CA5B Homo sapiens Human PF00194 7.1 Ki ChEMBL;BindingDB
Q9ULX7 CA14 Homo sapiens Human PF00194 7.0 Ki ChEMBL;BindingDB
P23219 PTGS1 Homo sapiens Human PF03098 6.6 Ki BindingDB
P22748 CA4 Homo sapiens Human PF00194 6.5 Ki ChEMBL;BindingDB
Q8N1Q1 CA13 Homo sapiens Human PF00194 6.4 Ki ChEMBL;BindingDB
P23280 CA6 Homo sapiens Human PF00194 6.2 Ki ChEMBL;BindingDB
P35218 CA5A Homo sapiens Human PF00194 6.0 Ki ChEMBL;BindingDB
Q6FTL6 NCE103 Candida glabrata (strain ATCC 2001 / BCRC 20586 / JCM 3761 / NBRC 0622 / NRRL Y-65 / CBS 138) Pathogen PF00484 7.0 Ki ChEMBL
P9WPJ9 mtcA2 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Pathogen PF00484 6.2 Ki ChEMBL;BindingDB
Q3I4V7 CAN2 Cryptococcus neoformans Pathogen PF00484 6.2 Ki ChEMBL;BindingDB
DrugBank Target Actions (7)
Target Gene Target Name Action Type
P11712 CYP2C9 Cytochrome P450 2C9 inhibitor enzymes
O60656 O60656 UDP-glucuronosyltransferase 1A9 substrate enzymes
P08684 CYP3A4 Cytochrome P450 3A4 substrate enzymes
P11712 CYP2C9 Cytochrome P450 2C9 substrate enzymes
P00918 CA2 Carbonic anhydrase 2 inhibitor targets
P07451 CA3 Carbonic anhydrase 3 inhibitor targets
P35354 PTGS2 Prostaglandin G/H synthase 2 inhibitor targets